See What HealthDay Can Do For You
Contact Us

N-Acetylcysteine Augmentation Therapy May Be Effective for OCD

Studied as augmentative agent to fluvoxamine in moderate-to-severe obsessive-compulsive disorder


MONDAY, March 7, 2016 (HealthDay News) -- N-acetylcysteine (NAC) appears to be effective as an augmentative agent for the treatment of obsessive-compulsive disorder (OCD), according to a study published online March 2 in the Journal of Clinical Pharmacy and Therapeutics.

Koosha Paydary, M.D., from the Tehran University of Medical Sciences in Iran, and colleagues conducted a double-blind, placebo-controlled trial involving patients with moderate-to-severe OCD. Forty-four patients were randomly allocated in a 1:1 ratio to receive fluvoxamine plus placebo (22 patients) or fluvoxamine plus NAC (22 patients). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was used to evaluate response to therapy at baseline and at weeks four, eight, and 10. Predesigned checklists were used to record side effects upon each visit.

The researchers observed a significant between-group effect for time × treatment interaction in the Y-BOCS total score (P = 0.012) and Y-BOCS obsession subscale (P = 0.011).

"Our results showed that NAC might be effective as an augmentative agent in the treatment of moderate-to-severe OCD," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.